Table 4.
Outcomes of Subsequent Meningiomas among Childhood Cancer Survivors
| Characteristic | General Population | Childhood Cancer Survivors with Subsequent Meningiomas | ||||||
|---|---|---|---|---|---|---|---|---|
| Study | National Cancer Data Base McCarthy BJ Journal of Neursurgery 1998; 88:831–839(20) | Ghim TT Cancer 1993; 71:4091 – 4095(36) | Goshen Y Pediatric Blood and Cancer 2007;49:294(37) | Hijiya N JAMA 2007;297:1207(22) | Walter AW Journal of Clinical Oncology 1998;16:3761–3767(35) | Taylor AJ Journal of Clinical Oncology 2009; 27:5781–5787(13) | Neglia JP J Natl Cancer Inst 2006;98:1528 – 37(7) | Vinchon M Child’s Nervous System 2011;27:445–453(33) |
| Year of Publication | 1998 | 1993 | 2007 | 2007 | 1998 | 2009 | 2010 | 2011 |
| Patients with Meningiomas | Benign: 1428 Atypical: 49 Malignant: 133 |
15 | 16 | 16 | 11 | 137 | 40 | 17 |
| STROBE Criteria(17) met, n/n | N/A | 11/31 | 19/30 | 25/31 | 25/30 | 30/33 | 31/32 | 20/32 |
| Study design | N/A | Cohort | Cohort | Cohort | Cohort | Cohort | Cohort | Cohort |
| Median age at first cancer diagnosis (range) | --- | 2·5 years (mean) (0·2 – 9 years) | 7·6 years (2 – 14 years) | n/a | 5 years (2·1 – 11·9 years) | n/a | n/a | 6·9 years (mean) (4·8 – 9·1 years) |
| Exposure to cranial radiation, % | --- | 100% | 15 (94%) | 16 (100%) | 11 (100%) | 134 (98%) | 60 (90%) | 11 (100%) |
| Median interval to second meningioma (range) | --- | 10·7 years (mean) (5 – 15 years) | 21 years (10 – 21 years) | 20·6 years (12·6 – 31·7 years) | 19·3 years (12·6 – 29 years) | 23·1 years (mean) | 17 years | 18·1 years (5·8 – 28·9 years) |
| Median age at second neoplasm diagnosis of a subsequent meningioma (range) | 0 – 44 years | 13·4 years (mean) (9 – 18 years) | 28·7 years (20 – 39 years) | n/a | 16·8 years | n/a | 25·5 years | n/a |
| Survival of patients with meningiomas, % | N/A | 11 (73%) | n/a | 15 (94%) | 11 (100%) | 95 (69%) | n/a | n/a |
| 5 year survival rate | Benign:89·1% Atypical: 77·9% Malignant:65·1% |
n/a | n/a | n/a | 100% | Low-Grade: 84·3% High-Grade: 57·3% |
n/a | n/a |